Rapport Therapeutics Inc. (RAPP)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know
Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High?
The consensus price target hints at a 75% upside potential for Rapport Therapeutics, Inc. (RAPP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 104.5% in Rapport Therapeutics, Inc. (RAPP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Rapport Therapeutics, Inc. (NASDAQ:RAPP ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT Company Participants Abraham Ceesay - CEO, President, Treasurer & Director Troy Ignelzi - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Hi, everyone, and thank you for joining us at our 2025 Fifth Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
Meloni and Trump: An Oval Office Meeting With Rapport and Banter
In their meeting, President Trump made clear that he had special regard for Prime Minister Giorgia Meloni of Italy. She said he had accepted an invitation to go to Rome.
